Loading…
Endogenous μ-opioid peptides modulate immune response towards malignant melanoma
: Opioids exert major effects not only in the central nervous system but also in immune responses. We investigated the effects of μ‐opioid peptides, secreted by tumor cells, on anti‐tumor immune responses. For this purpose, tumor growth was studied in wild‐type and μ‐opioid receptor–deficient (MOR−...
Saved in:
Published in: | Experimental dermatology 2011-01, Vol.20 (1), p.24-28 |
---|---|
Main Authors: | , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | : Opioids exert major effects not only in the central nervous system but also in immune responses. We investigated the effects of μ‐opioid peptides, secreted by tumor cells, on anti‐tumor immune responses. For this purpose, tumor growth was studied in wild‐type and μ‐opioid receptor–deficient (MOR−/−) mice injected with B16 melanoma cells. The ability of these cells to produce opioids was studied by Western blots in vitro. Finally, biopsy material from human melanomas was investigated by immunohistochemistry for ß endorphin expression. Injection of B16 melanoma cells, producing endogenous ß endorphin, in the flank of MOR−/− mice revealed a profound reduction in tumor growth, paralleled by a significantly higher infiltration of immune cells into the tumors, when compared to tumor growth after injection of B16 melanoma cells into wild‐type mice. Opioids present in B16 cell supernatant significantly reduced the proliferation of normal but not MOR−/− leucocytes. Immunohistochemical analyses of biopsies from human melanoma tissues showed a positive correlation between expression of ß endorphin and tumor progression. Our data provide evidence that μ‐opioid peptides may play a major role in cancer progression by modulating immune response. This finding may have implications for the future optimization of immunointerventions for cancer. |
---|---|
ISSN: | 0906-6705 1600-0625 |
DOI: | 10.1111/j.1600-0625.2010.01158.x |